Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
Terns Pharmaceuticals (Nasdaq: TERN) granted inducement equity awards to three new employees effective April 1, 2026.
Rhea-AI Summary
Terns Pharmaceuticals (Nasdaq: TERN) granted inducement equity awards to three new employees effective April 1, 2026. The Compensation Committee approved a total of 23,316 restricted stock units (RSUs) under the 2022 Employment Inducement Award Plan, vesting over four years subject to continued service.
The awards were made in accordance with Nasdaq Listing Rule 5635(c)(4) as material inducements to accept employment with the company.
Positive
- None.
Negative
- None.
Details
News Market Reaction – TERN
In the Apr 6 session, TERN gained 0.11%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- RSUs granted
- 23,316 RSUs
- Aggregate inducement awards to three new employees as of April 1, 2026
- Vesting period
- 4 years
- RSUs vest over four years, subject to continued service
- New employees
- 3 employees
- Recipients of equity inducement awards under 2022 plan
Historical Context
-
Mar 26
Shareholder rights review
- 24h Move
- +0.6%
Article questioning whether shareholders are receiving fair deal terms.
-
Merck agrees to acquire Terns for $53.00 per share in cash.
-
Management to present at multiple March 2026 investor conferences.
-
Equity inducement awards to two employees under 2022 plan.
-
Detailed TERN-701 trial status, milestones, Fast Track and strong cash runway.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
equity inducement awards financial
restricted stock units financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
FOSTER CITY, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that it has granted as of April 1, 2026 equity inducement awards to three new employees under the terms of the 2022 Employment Inducement Award Plan, as amended. The equity awards were approved by the Compensation Committee of the Company’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and were made as a material inducement to the employees’ acceptance of employment with Terns.
The Company granted 23,316 restricted stock units (the “RSUs”), in the aggregate, of Terns common stock to the new employees. The RSUs vest over four years, subject to the employees’ continued service through the applicable vesting dates.
About Terns Pharmaceuticals
Terns Pharmaceuticals is a clinical-stage oncology company reimagining known biology to deliver high impact medicines. Our lead program, TERN-701, is a highly selective, oral, allosteric BCR-ABL inhibitor with a potentially best-in-disease profile that could meaningfully improve upon the efficacy, safety and convenience of existing treatments for chronic myeloid leukemia. For more information, please visit: www.ternspharma.com.
Contacts for Terns
Investors
Justin Ng
investors@ternspharma.com
Media
Jenna Urban
CG Life
media@ternspharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.